Takeaway
- 55.8% of patients with differentiated thyroid cancer (DTC) perceived that they did not have a choice about whether to receive radioactive iodine (RAI) therapy, according to survey results.
Why this matters
- Despite unclear benefits in patients with DTC, RAI but is still a common treatment option.
- Findings underscore a need for more shared decision-making.
Key results
- 75.9% of patients received RAI.
- 55.8% of patients responded that they did not have a choice in receiving RAI.
- Perception of no choice was more likely when the physician strongly recommended RAI (aOR, 1.56; 95% CI, 1.13-2.17).
- Patients who felt they did not have a choice were more likely to receive RAI (aOR, 2.50; 95% CI, 1.64-3.82) and report lower decision satisfaction (aOR, 2.31; 95% CI, 1.67-3.20).
- Odds of receiving RAI were greater for patients with N1 disease compared with those with N0 disease (aOR, 2.44; 95% CI, 1.42-4.17).
Study design
- 2632 patients with DTC from the Georgia and Los Angeles Surveillance, Epidemiology, and End Results registries responded to the survey; 1319 (999 who received RAI, 320 who did not) were included in the study after analytic exclusions.
- Funding: National Cancer Institute; California Department of Public Health; CDC.
Limitations
- Potential recall bias.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionalsLogin to
account
Don’t have an account? Get started